The Conversation (0)
InMed Pharmaceuticals shared the publication of a peer-reviewed article Drug Delivery and Translational Research showing pre-clinical study results from research co-sponsored by InMed.
InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) shared the publication of a peer-reviewed article Drug Delivery and Translational Research showing pre-clinical study results from research co-sponsored by InMed.
As quoted in the press release:
The article, titled “A stimulus-responsive, in situ forming, nanoparticle-laden hydrogel for ocular drug delivery”, presents results from a pre-clinical study co-sponsored by InMed and was co-authored by Dr. Sazzad Hossain, InMed’s Chief Scientific Officer.
In October, 2017, InMed originally announced completion of this study. These proprietary data support what the Company believes to be a first-in-class nanoparticle-hydrogel formulation for cannabinoid delivery to the eye, resulting in enhanced drug uptake via the cornea and lens. The patent family for this discovery is currently at the provisional stage and will be converted to a PCT filing during 2018.
